Reconsidering the Design of Phase II/III Clinical Trials to Ensure Patients Overcome Challenges with Standard Control Arms for More Streamlined Trials
- Discussing strategies for molecular profiling and imaging biomarkers to successfully stratify patients for clinical trials
- Exploring innovative control arms using AI and predictive measure to address budget constraints and patient recruitment challenges
- Overcoming current standard of care involving toxic agents such as TMZ that might hinder the potential benefits of novel therapeutics